Instil Bio Inc
NASDAQ:TIL
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
10.78
37.565
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Instil Bio Inc
Non-Reccuring Items
Instil Bio Inc
Non-Reccuring Items Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Non-Reccuring Items | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
I
|
Instil Bio Inc
NASDAQ:TIL
|
Non-Reccuring Items
-$17m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Non-Reccuring Items
-$10.7B
|
CAGR 3-Years
-72%
|
CAGR 5-Years
-60%
|
CAGR 10-Years
-27%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Non-Reccuring Items
-$843m
|
CAGR 3-Years
38%
|
CAGR 5-Years
32%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Non-Reccuring Items
-$3.2B
|
CAGR 3-Years
-87%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-35%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Non-Reccuring Items
-$543m
|
CAGR 3-Years
-74%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-60%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Non-Reccuring Items
-$245.5m
|
CAGR 3-Years
26%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
-20%
|
|
Instil Bio Inc
Glance View
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engages in developing cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company is headquartered in Dallas, Texas and currently employs 412 full-time employees. The company went IPO on 2021-03-19. The firm is focused on developing a cell therapy pipeline of autologous tumor-infiltrating lymphocyte (TIL) therapies for the treatment of patients with cancer. TIL therapies leverage platform for TIL manufacturing has been designed for the scalability, logistics, and accessibility of TIL therapy. The company is advancing its lead TIL product candidate, ITIL-168, for the treatment of advanced melanoma. The company is also developing a class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR) platform. ITIL-168 is an autologous TIL therapy that it is initially developed for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma. Its pipeline also includes ITIL-306, its CoStAR-TIL product candidate.
See Also
What is Instil Bio Inc's Non-Reccuring Items?
Non-Reccuring Items
-17m
USD
Based on the financial report for Dec 31, 2024, Instil Bio Inc's Non-Reccuring Items amounts to -17m USD.
What is Instil Bio Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
76%
Over the last year, the Non-Reccuring Items growth was 76%.